Huatai United Securities Co., Ltd.’s special verification opinions on the storage, management and actual use of funds raised by Beijing Innotek Biotechnology Co., Ltd. in 2025

Huatai United Securities Co., Ltd.

About Beijing Innotek Biotechnology Co., Ltd.

Special verification opinions on the storage, management and actual use of raised funds in 2025

Huatai United Securities Co., Ltd. (hereinafter referred to as "Huatai United" or the "Sponsor"), as the sponsor of the initial public offering of Beijing Innotech Biotechnology Co., Ltd. (hereinafter referred to as "Innotech" or the "Company") and its listing on the Science and Technology Innovation Board, in accordance with the "Measures for the Administration of Sponsorship Business for Securities Issuance and Listing", "Supervisory Rules for Fund Raising by Listed Companies", "Shanghai Stock Exchange Science and Technology Innovation Board Stock Listing Rules" and "Shanghai Stock Exchange Science and Technology Innovation Board Listed Companies Self-Regulatory Supervision Guidelines No. 1" No. - Standardized Operations" and other laws and regulations, the deposit, management and actual use of funds raised by Innotech in 2025 have been carefully verified. The verification situation and verification opinions are as follows:

1. Basic information on raising funds

(1) Actual amount of funds raised and availability of funds

According to the "Reply on Approving the Initial Public Offering Registration of Beijing Innotek Biotechnology Co., Ltd." (CSRC License [2022] No. 902) issued by the China Securities Regulatory Commission (hereinafter referred to as the "CSRC") on April 28, 2022, and with the consent of the Shanghai Stock Exchange, the company will publicly issue 34,020,000 RMB ordinary shares (A shares) to the public for the first time in July 2022, with a par value of RMB 1.00 per share. Yuan, the issue price per share is RMB 26.06, and the total raised funds are RMB 886,561,200. After deducting the issuance expenses (including value-added tax, excluding the 1,500,000 yuan in sponsorship fees paid in advance and included in the profit and loss), the net amount of funds raised is RMB 800,482,900, and all the above funds have been received. Daxin Accounting Firm (Special General Partnership) verified the company's funding for the public issuance of new shares and issued a "Capital Verification Report" on July 25, 2022 (Daxin Yanzi [2022] No. 34-00009).

(2) Use and balance of raised funds

As of December 31, 2025, the actual use and balance of the company's raised funds are as follows:

Item Amount (RMB)

Total amount of raised funds received 886,561,200.00 Less: payment of issuance expenses 86,078,291.18 Net amount of raised funds 800,482,908.82 Less: funds used for investment projects in previous years (including actual funds used

489,882,668.64 replacement advance investment amount)

Funds used for investment projects this year 53,483,169.87 Balance of idle raised funds for cash management 132,000,000.00 Accumulated bank fees paid 2,225.24 Plus: Accumulated interest income (including income from financial products) 26,113,712.88

As of December 31, 2025, the balance of the special account for raised funds is 151,228,557.95

2. Storage and management of raised funds

(1) Management system of raised funds

In order to standardize the management and use of raised funds and protect the rights and interests of investors, the company has formulated the "Measures for the Management of the Use of Raised Funds of Beijing Innotek Biotechnology Co., Ltd." (August 2025) in accordance with the "Company Law of the People's Republic of China", "Securities Law of the People's Republic of China", "Stock Listing Rules of the Shanghai Stock Exchange's Science and Technology Innovation Board", "Self-Discipline Supervision Guidelines for Companies Listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange No. 1 - Standardized Operations" and other laws and regulations, combined with the actual situation of the company. (revised in March) (hereinafter referred to as the "Measures for the Management of the Use of Raised Funds"), the "Measures for the Management of the Use of Raised Funds" have been reviewed and approved at the 10th meeting of the company's second board of directors and the first extraordinary general meeting of shareholders in 2025.

(2) Fund raising supervision agreement

2022 6 In August, the company and the sponsoring institution Huatai United signed a "Tripartite Supervision Agreement for the Special Account Storage of Raised Funds" with the Bank of Beijing Co., Ltd. Financial Harbor Branch, the Bank of Communications Co., Ltd. Beijing Fengtai Branch, and the Agricultural Bank of China Co., Ltd. Beijing Asian Games Village Branch. The company and its wholly-owned subsidiary Innotek (Tangshan) Biotechnology Co., Ltd. (hereinafter referred to as "Tangshan Innotek") signed a "Four-party Supervision Agreement for the Special Account Storage of Raised Funds" with Huatai United and China Merchants Bank Co., Ltd. Beijing Fengtai Science and Technology Park Branch.

In November 2022, the company and its wholly-owned subsidiary Tangshan Innotek signed the "Supplementary Agreement to the Special Account Supervision Agreement for Raised Funds" with Huatai United, Beijing Fengtai Branch of Bank of Communications Co., Ltd., and Financial Harbor Branch of Bank of Beijing Co., Ltd., adding Tangshan Innotek as the user of raised funds. In June 2024, the company and its wholly-owned subsidiary Tangshan Innotek, and its branch Beijing Innotek Biotechnology Co., Ltd. Hangzhou Branch (hereinafter referred to as the "Hangzhou Branch") signed the "Supplementary Agreement (2) to the Special Account Supervision Agreement for Raised Funds" with the Beijing Fengtai Branch of Bank of Communications Co., Ltd., supplementing the Hangzhou Branch as the user of raised funds. In November 2024, the company and its wholly-owned subsidiary Tangshan Innotek, Hangzhou Branch, and wholly-owned subsidiary Guangzhou Linshangyuan Biotechnology Co., Ltd. (hereinafter referred to as "Lingshangyuan") signed the "Supplementary Agreement (3) to the Special Account Supervision Agreement for Raised Funds" with the Beijing Fengtai Branch of Bank of Communications Co., Ltd., supplementing Linshangyuan as the user of the raised funds.

The above-mentioned supervision agreement clarifies the rights and obligations of all parties, and the main terms of the agreement are not significantly different from the Shanghai Stock Exchange's "Tripartite Supervision Agreement for the Deposit of Raised Funds in a Special Account (Template)". As of December 31, 2025, the above-mentioned regulatory agreement was performed normally.

During the reporting period, the company strictly abided by various systems, used the raised funds according to the purpose of the raised funds, and provided relevant information on the use of special account funds to the sponsor in accordance with the requirements of the "Tripartite Supervision Agreement on Raised Funds".

(3) Deposit of raised funds in special account

As of December 31, 2025, the balance of the special account for raising funds is as follows:

Ending amount Name of account holder Name of account opening bank Bank account

(Yuan) Beijing Innotech Bank of Communications Co., Ltd.

110061242013003765001 17,447,375.49 Shu Technology Co., Ltd. Beijing Fengtai Branch

Beijing Innotech China Merchants Bank Co., Ltd.

110927877610808 127,639,060.83 Technology Co., Ltd. Beijing Fengtai Science and Technology Park Branch

Innotek (Tangshan) Student China Merchants Bank Co., Ltd.

311900245910402 4,074,364.98 Biotechnology Co., Ltd. Beijing Fengtai Science and Technology Park Branch

Innotech (Tangshan) Bank of Communications Co., Ltd.

110061242013004532659 1,018,895.50 Wu Technology Co., Ltd. Beijing Fengtai Branch

Beijing Innotech

Bank of Communications Co., Ltd.

Technology Co., Ltd. Hangzhou 110061242013006941152 558,928.97

Beijing Fengtai Branch

State branch

Guangzhou Lingshangyuan Biotechnology Bank of Communications Co., Ltd.

110061242013007418506 489,932.18 Technology Co., Ltd. Beijing Fengtai Branch

Beijing Innotech Bank of Beijing Co., Ltd.

20000042793300094552478 Canceled Hushu Co., Ltd. Financial Harbor Branch

Beijing Innotech Biotechnology Agricultural Bank of China Co., Ltd.

11231401040005390 Canceled Hushu Co., Ltd. Beijing Beiyuan Home Branch

Innotek (Tangshan) Student Bank of Beijing Co., Ltd.

20000062602900110156582 Canceled Huwu Technology Co., Ltd. Financial Harbor Branch

Total 151,228,557.95

Note 1: Agricultural Bank of China Co., Ltd. Beijing Asian Games Village Branch is the superior management bank of Agricultural Bank of China Co., Ltd. Beijing Beiyuan Jiayuan Branch. According to bank management requirements, the "Tripartite Supervision Agreement for Special Account Deposit of Raised Funds" is signed by Agricultural Bank of China Co., Ltd. Beijing Asian Games Village Branch, but the account opening behavior is Agricultural Bank of China Co., Ltd. Beijing Beiyuan Jiayuan Branch.

3. Actual use of funds raised in 2025

(1) Usage of funds for investment projects with raised funds (hereinafter referred to as “raised investment projects”)

As of December 31, 2025, for details on the use of funds raised for investment projects, please refer to the "Comparison of the Use of Raised Funds" (Appendix 1).

(2) Advance investment and replacement of fundraising projects

During the reporting period, the company did not make any advance investment or replacement in fundraising projects.

(3) Temporarily supplementing working capital with idle raised funds

During the reporting period, the company did not use idle raised funds to temporarily replenish working capital.

(4) Cash management of idle raised funds

The company held the sixth meeting of the second board of directors and the sixth meeting of the second board of supervisors on August 28, 2024, and reviewed and approved the "Proposal on the Use of Temporarily Idle Raised Funds for Cash Management" and agreed that the company would use idle raised funds not exceeding RMB 350 million (including the original amount). The funds are used for cash management and are used to purchase financial products or deposit products with high security and good liquidity (including but not limited to agreement deposits, call deposits, structured deposits, time deposits, certificates of deposit, etc.), which can be used on a rolling basis within 12 months from the expiration date of the previous authorization for cash management, that is, September 2, 2024 to September 1, 2025.

The company held the 10th meeting of the second board of directors and the 10th meeting of the second board of supervisors on August 27, 2025, and reviewed and approved the "Proposal on the Use of Temporarily Idle Raised Funds for Cash Management", agreeing that the company will use idle raised funds not exceeding RMB 300 million (inclusive) for cash management to purchase capital-guaranteed financial products with high security and good liquidity (including but not limited to notice deposits, structured deposits, large certificates of deposit, etc.), starting from the expiration date of the previous authorization for cash management It can be used on a rolling basis within 12 months, that is, from September 2, 2025 to September 1, 2026.

As of December 31, 2025, the company's balance of using temporarily idle raised funds for cash management was 132.00 million yuan. The details are as follows:

Product Category Investment Amount Estimated Annual Collection Number Trustee Purchase Date Maturity Date

Type (10,000 yuan) Yield China Merchants Bank Beijing Feng 7-day Pass

1 900.00 2022/9/8 Not applicable 2.10% Taiwan Science and Technology Park Branch Zhi Deposit

China Merchants Bank Beijing Feng 7-day Pass

2 11,300.00 2022/12/28 Not applicable 2.00% Taiwan Science and Technology Park Branch Zhidao

Bank of Communications Beijing Feng Structural

3 1,000.00 2025/12/8 2026/2/9 0.65%-1.4%

Taiwan branch deposit

(5) The excess raised funds are used for projects under construction and new projects (including acquisition of assets, etc.) or the repurchase and cancellation of company shares

During the reporting period, the company did not use excess raised funds for projects under construction or new projects (including acquisition of assets, etc.) or to repurchase and cancel the company's shares.

(6) Usage of surplus raised funds

On August 27, 2025, the company held the 10th meeting of the second board of directors and the 10th meeting of the second board of supervisors, and reviewed and approved the "Proposal on Using Part of the Surplus Raised Funds for Other Raised Investment Projects and the Extension of Raised Investment Projects", and agreed that the company would use 60 million yuan of the remaining raised funds to invest in "in vitro diagnostic product research and development projects" that are more suitable for the company's current needs; it was agreed that the company would extend the time for the "in vitro diagnostic product research and development projects" to reach the scheduled usable state by 18 months, by Adjusted from October 2025 to April 2027.

(7) Other situations of use of raised funds

The company held the twelfth meeting of the first board of directors and the ninth meeting of the first board of supervisors on September 23, 2022, and reviewed and approved the "Proposal on Using Self-raised Funds to Pay Part of the Funds for Raised Investment Projects and Subsequent Replacement with Raised Funds in Equal Parts". It was agreed that the company and its subsidiaries would use part of the self-raised funds to pay for the funds required for the raised investment projects according to the actual situation during the implementation of the raised capital investment projects, and transfer equal amounts of funds from the raised funds special account to the implementation entity's own capital account for replacement.

The company held the ninth meeting of the second board of directors and the ninth meeting of the second board of supervisors on April 24, 2025, and reviewed and approved the "Proposal on Increasing the Implementation Content of Raised Investment Projects" and agreed that the company would increase the implementation content of the "In Vitro Diagnostic Product R&D Project" and related investments in "self-research, technology introduction and product research and development related to the new layout technology platform."

4. Change the use of funds for investment projects

(1) Changes in investment projects with raised funds

During the reporting period, the company did not change the investment projects with raised funds.

(2) External transfer or replacement of investment projects with raised funds

During the reporting period, the company had no external transfer or replacement of investment projects with raised funds.

5. Problems in the use and disclosure of raised funds

During the reporting period, there were no violations in the use and disclosure of funds raised by the company.

6. Accountant’s assurance opinion on the special report on the storage, management and use of raised funds

After verification, Daxin Accounting Firm (Special General Partnership) believes that: the special report on the storage, management and actual use of raised funds prepared by the company complies with relevant regulations and fairly reflects the actual storage, management and actual use of raised funds in 2025 in all major aspects.

7. Main verification work of the sponsor

The sponsor representative verified the storage, management and use of funds raised by Innotek and the implementation of investment projects with raised funds through various methods such as data review and daily communication. The main verification contents include: reviewing the company's bank statement of the deposit of raised funds, original vouchers for the use of raised funds, relevant reports of intermediaries, relevant announcements and supporting documents on the deposit, management and actual use of raised funds, and communicating with the company's directors, senior managers and other relevant personnel.

8. Verification Opinions of the Sponsor

After verification, the sponsoring agency believes that in 2025, the company's storage, management and actual use of raised funds complied with the provisions of the "Shanghai Stock Exchange Science and Technology Innovation Board Stock Listing Rules", "Supervisory Rules for Listed Companies' Raised Funds" and "Shanghai Stock Exchange Science and Technology Innovation Board Self-Regulatory Guidelines No. 1 - Standardized Operations" and other regulations and documents. Raised funds were stored and used in special accounts, and relevant information disclosure obligations were fulfilled in a timely manner. There was no violation of relevant laws and regulations in the use of raised funds.

The sponsor has no objection to the special report disclosed by the company's board of directors on the deposit, management and actual use of funds raised in 2025.

(This page has no text, but is the signature page of the "Special Verification Opinions of Huatai United Securities Co., Ltd. on the Deposit, Management and Actual Use of Funds Raised in 2025 by Beijing Innotek Biotechnology Co., Ltd.")

Sponsor representative (signature)

Ding Mingming Zheng Mingxin

Huatai United Securities Co., Ltd.

Year Month Date Attachment 1: Comparison table of usage of raised funds

Unit: 10,000 yuan

Total raised funds 80,048.29 Total raised funds invested this year 5,348.32

Total amount of raised funds changed use 31,320.01

The total amount of raised funds that have been invested is 54,336.58 The proportion of the total raised funds that have been changed in use is 39.13%

Accumulated by the end of the period

Changed items It is feasible to invest as of the end of the period

The amount of funds raised is committed as of the end of the period. The project has reached the expected amount as of the end of the period. Has it been achieved this year?

Committed investment projects, including some adjusted investments. Is the progress of investment this year progressing?

Commitment of investment Commitment of investment amount Cumulative investment and commitment of investment Determined usable status Achieved to expected

Item changes (such as total deposit amount (%) (4) = major changes

Total (1) Amount (2) Difference in Amount Status Date Benefit Benefit

Yes) (2)/(1)

(3)＝(2)-(1)

In vitro diagnostic products

Product R&D and production

Yes 35,309.00 25,000.00 650.24 - 650.40 0.16 100.02 Terminated Not applicable Not applicable Not applicable Industrialization projects

(Issue 1)

In vitro diagnostic products

Yes 14,196.00 14,196.00 27,166.25 5,348.32 19,039.19 -8,127.06 70.08 April 2027 Not applicable Not applicable No product research and development project

Marketing and services

Network construction project Yes 25,567.00 6,000.00 977.99 - 977.99 - 100.00 Terminated Not applicable Not applicable Not applicable to the purpose

Information platform

Yes 5,874.00 2,000.00 51.77 - 51.77 - 100.00 Terminated Not applicable Not applicable Not applicable Construction projects

Supplement working capital

No 40,000.00 32,852.29 32,852.29 - 33,617.25 764.96 102.33 Not applicable Not applicable Not applicable Not applicable

temporary deposit

Not applicable Not applicable Not applicable 18,349.76 - - -18,349.76 - Not applicable Not applicable Not applicable Not applicable

Total - 120,946.00 80,048.29 80,048.29 5,348.32 54,336.58 -25,711.71 67.88 - - - -

As the company plans to use the remaining 60 million yuan in raised funds for "in vitro diagnostic product research and development projects" to promote the research and development of EU IVDR products, US FDA products and nervous system marker detection-related products, the company fully considers the current project construction progress and the reasons for not meeting the planned progress, the use of raised funds, strictly controls the overall quality of the project, and safeguards the interests of all shareholders and the company. On August 27, 2025 (specific fundraising projects) On the same day, the company held the 10th meeting of the second board of directors and the 10th meeting of the second board of supervisors, and reviewed and approved the "Proposal on Using Part of the Surplus Raised Funds for Other Raised Investment Projects and the Extension of Raised Investment Projects", and agreed that the company would extend the time for the "in vitro diagnostic product research and development project" to reach the scheduled usable state by 18 months, from October 2025 to April 2027.

Project feasibility occurs

Not applicable

Description of major changes

Raising funds for investment projects

Not applicable

Early investment and replacement status

Use idle funds to raise funds

Not applicable

Temporarily replenish working capital situation

The company held the sixth meeting of the second board of directors and the sixth meeting of the second board of supervisors on August 28, 2024, and reviewed and approved the "Proposal on the Use of Temporarily Idle Raised Funds for Cash Management" and agreed that the company would raise idle funds not exceeding RMB 350 million (including the original amount). The funds are used for cash management and are used to purchase financial products or deposit products with high security and good liquidity (including but not limited to agreement deposits, call deposits, structured deposits, time deposits, certificates of deposit, etc.). The idle raised funds will be processed in December from the expiration date of the previous cash management authorization. It can be used on a rolling basis, that is, from September 2, 2024 to September 1, 2025.

Cash management, investment related products The company held the 10th meeting of the second board of directors and the 10th meeting of the second board of supervisors on August 27, 2025, and reviewed and approved the "Proposal on the Use of Temporarily Idle Raised Funds for Cash Management" and agreed that the company would use idle raised funds not exceeding RMB 300 million (including the original amount) for cash management. Cash management is used to purchase capital-guaranteed financial products with high security and good liquidity (including but not limited to call deposits, structured deposits, large certificates of deposit, etc.). It can be used on a rolling basis within 12 months from the expiration date of the previous cash management authorization, that is, from September 2, 2025 to September 1, 2026.

Use super-raised funds to permanently replenish liquidity

Not applicable

or repayment of bank loans

Amount of balance of raised funds and reasons for formation Not applicable

The company held the twelfth meeting of the first board of directors and the ninth meeting of the first board of supervisors on September 23, 2022, and reviewed and approved the "Proposal on Using Self-raised Funds to Pay Part of the Funds for Raised Investment Projects and Subsequent Replacement with Raised Funds in Equal Parts", agreeing that the company and its subsidiaries will use part of the self-raised funds to pay for the funds required for the raised investment projects according to actual conditions during the implementation of the raised capital investment projects, and transfer equal amounts of funds from the raised funds special account to the self-owned capital account of the implementation entity for replacement.

The company held the ninth meeting of the second board of directors and the ninth meeting of the second board of supervisors on April 24, 2025, and reviewed and approved the "Proposal on Increasing the Implementation Content of Raised Investment Projects" and agreed that the company would increase the implementation content of the "In Vitro Diagnostic Product R&D Project" and related investments in "self-research, technology introduction and product research and development related to the new layout technology platform."

Note 1: The "committed investment amount as of the end of the period" is determined based on the latest disclosed investment plan for raised funds.

Note 2: The total amount of funds raised refers to the net amount of funds raised after deducting issuance expenses (including value-added tax, excluding the 1.5 million yuan in sponsorship fees paid in the previous period and included in profit and loss). Note 3: The difference between the cumulative investment amount of the supplementary working capital project as of the end of the period and the committed investment amount is the relevant interest.

Note 4: There may be slight differences in the mantissa between the partial total and the direct sum of the sub-items due to rounding differences.